New Frontiers and Treatment Advances in Rheumatoid Arthritis


Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

1.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the understanding of treatment advances in rheumatoid arthritis.

Release Date

July 28, 2015

Expiration Date

July 28, 2017

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period July 28, 2015 through July 8, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 5 segments totaling 1.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.


Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The University of Massachusetts Medical School designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

Mark C. Genovese, MD
Program Chair

James W. Raitt Endowed Professor of Medicine
Co-Chief, Division of Immunology and Rheumatology
Stanford University
Stanford, California

Grants/Research Support: AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Crescendo Pharmaceuticals, Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, and Vertex/A; Japan Tobacco, Principia Biopharma, Pharmacyclics/C; Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Lilly, Novartis, Pfizer, Roche, Sanofi, UCB, and Vertex/G.

Ernest Choy, MD, FRCP
Professor of Rheumatology
Sir Alfred Baring Garrod Clinical Trials Unit
Academic Department of Rheumatology
King’s College London
London, England

Research grants. advisory boards and speaker bureaus: Abbott Laboratories, Allergan, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Chelsea Therapeutics, Chugai Pharma, Daiichi Sankyo, Eli Lilly, Ferring Pharmacuetical, GSK, Hospita, ISIS, Jazz Pharmaceuticals, Jenssen, MedImmune, Merrimack Pharmaceutical, MSD, Napp, Novimmune, Novartis, Pfizer, Pierre Fabre Medicament, Regeneron, Roche, Sanofi-Aventis, Schering Plough, Synovate, Tonix and UCB.

Roy M. Fleishmann, MD
Clinical Professor of Medicine
University of Texas Southwestern Medical Center at Dallas
Co-Director, Division of Rheumatology
Texas Health Presbyterian Medical Center
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas

Consultant: AbbVie, Akros, Amgen, Ardea, Astra Zeneca, Augurex, BMS, Celgene, Genentech, GSK, Iroko, Janssen, Eli Lilly, Pfizer, Principia, Roche, Sanofi Aventis, UCB
Clinical Trial Grants: AbbVie, Amgen, Ardea, Astra Zeneca, BMS, Boehringer Ingelheim, Celgene, Genentech, GSK, Janssen, Eli Lilly, Merck, Pfizer, Prinicipia, Resolve, Roche, Sanofi Aventis, SmithKlineGlaxo, UCB, Vertex

Eric Ruderman, MD
Professor of Medicine
Division of Rheumatology
Northwestern University, Feinberg School of Medicine
Chicago, Illinois

Advisor/Consultant: AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Pfizer, Genentech, Vertex, UCB
Grants/Research Support: Pfizer, Celgene

Program Managers and Web Editor Disclosure

Program Manager Gideon Bosker, MD has nothing to disclose.
Program Reviewer Denise Leary has nothing to disclose.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Explain the role the IL-6 signaling system and the role of this cytokine in the immunobiology and clinical manifestations of RA
  • Detail both the localized, articular and systemic manifestations of RA, and the role of specific therapies in mitigating local and systemic symptomology associated with RA
  • Describe the significant unmet medical needs in patients with RA, especially those who fail or respond to initial therapy with methotrexate or who have had an inadequate response to initial biologic therapy
  • Identify subpopulations of RA patients who, due to suboptimal response, side effect, or quality-of-life issues associated with methotrexate, may require intensification of therapy with IL-6 targeting or other immunomodulatory therapies
  • Manage challenging and/or unusual subgroups of patients with RA, including the elderly, men with RA, obese patients, and patients who manifest poor regimen adherence due to quality-of-life- issues or poor treatment response

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2015 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.




I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC



Key Program Topics Include:

Anti B Cell
Anti IL6
Anti T cell



IL-6 Inhibitors
IL-6 Signaling Pathway
Kinase Pathways
LORHEN Registry:
Rheumatoid Arthritis